Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and immunogenicity of HIV envelope protein trimers and related vaccine components. The regimens use heterologous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 16055 NFL Delta Gly4 Env Protein Trimer (Env protein trimer)
• 3M-052-AF + Alum Adjuvant (adjuvant)
• Ad4-Env145NFL Viral Particles (viral particle vaccine component)
• Trimer 4571 (Env protein trimer)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 1 | Status: ACTIVE_NOT_RECRUITING